0
0
Analysis of Semaglutide Clinical Trials Provides Insight into Long-Term Effects of Wegovy
Two recent analyses of the extensive clinical trial of semaglutide, the key component of the weight loss medication Wegovy, have offered valuable insights into the sustained effects of this popular drug. The studies, presented at the European Congress on Obesity in Venice, Italy, highlighted the long-term benefits experienced by individuals using Wegovy, regardless of the amount of weight lost. These findings support the argument for broader coverage of this costly medication by insurers and governments.
Sustained Weight Loss
An in-depth analysis of the SELECT clinical trial involving more than 17,000 participants revealed that individuals using Wegovy experienced an average weight loss of 10% after 65 weeks, with this weight loss being maintained for up to four years. The study, recently published in the highly respected scientific journal Nature Medicine, emphasized the profound implications of achieving such substantial weight loss across a diverse population. The authors of the study noted that this level of weight reduction could potentially alleviate the public health burden associated with various obesity-related health conditions.
Cardiovascular Health Benefits
Earlier results from the SELECT trial had shown that Wegovy significantly reduced the risk of serious cardiovascular events, such as strokes and heart attacks, by 20%. A fresh analysis of the trial revealed that individuals taking Wegovy continued to experience these cardiovascular benefits irrespective of their initial body weight or the amount of weight lost while using the medication. Professor John Deanfield from University College London, UK, who spearheaded the study, highlighted the independent nature of the treatment effect associated with semaglutide. This suggests that the drug possesses additional cardiovascular benefits beyond its capacity to reduce unhealthy body fat.
Image/Photo credit: source url
